PEPGEN INC. Net Income
PEPGEN INC. (PEPG) reported Net Income of -$17.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-08-06
- PEPGEN INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$17.81M.
- PEPGEN INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$17.76M.
- PEPGEN INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$18.34M.
- PEPGEN INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$18.03M.
- PEPGEN INC. net income (loss) attributable to parent for fiscal 2025 was -$89.66M.
- PEPGEN INC. net income (loss) attributable to parent for fiscal 2024 was -$89.98M.
- PEPGEN INC. net income (loss) attributable to parent for fiscal 2023 was -$78.63M.
- PEPGEN INC. net income (loss) attributable to parent for fiscal 2022 was -$69.10M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$17.81M 10-Q · filed 2026-08-06 | -$35.58M 10-Q · filed 2026-08-06 | -$53.91M derived: sum of 3 quarters · filed 2026-08-06 | -$71.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$17.76M 10-Q · filed 2026-08-06 | -$36.10M derived: sum of 2 quarters · filed 2026-08-06 | -$54.13M derived: sum of 3 quarters · filed 2026-08-06 | -$77.22M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$18.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$36.37M derived: sum of 2 quarters · filed 2026-03-04 | -$59.45M derived: sum of 3 quarters · filed 2026-08-06 | -$89.66M 10-K · filed 2026-03-04 |
| 2025-09-30 | -$18.03M 10-Q · filed 2025-11-12 | -$41.11M derived: sum of 2 quarters · filed 2026-08-06 | -$71.31M 10-Q · filed 2025-11-12 | -$93.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$23.09M 10-Q · filed 2026-08-06 | -$53.29M 10-Q · filed 2026-08-06 | -$75.53M derived: sum of 3 quarters · filed 2026-08-06 | -$96.92M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$30.20M 10-Q · filed 2026-08-06 | -$52.44M derived: sum of 2 quarters · filed 2026-08-06 | -$73.83M derived: sum of 3 quarters · filed 2026-08-06 | -$102.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$22.24M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$43.63M derived: sum of 2 quarters · filed 2026-03-04 | -$71.96M derived: sum of 3 quarters · filed 2026-03-04 | -$89.98M 10-K · filed 2026-03-04 |
| 2024-09-30 | -$21.38M 10-Q · filed 2025-11-12 | -$49.72M derived: sum of 2 quarters · filed 2025-11-12 | -$67.74M 10-Q · filed 2025-11-12 | -$87.23M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-06-30 | -$28.34M 10-Q · filed 2025-11-12 | -$46.35M 10-Q · filed 2025-08-07 | -$65.85M derived: sum of 3 quarters · filed 2025-11-12 | -$89.14M derived: sum of 4 quarters · filed 2025-11-12 |
| 2024-03-31 | -$18.02M 10-Q · filed 2025-11-12 | -$37.52M derived: sum of 2 quarters · filed 2025-11-12 | -$60.80M derived: sum of 3 quarters · filed 2025-11-12 | -$80.33M derived: sum of 4 quarters · filed 2025-11-12 |
| 2023-12-31 | -$19.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | -$42.78M derived: sum of 2 quarters · filed 2025-02-24 | -$62.31M derived: sum of 3 quarters · filed 2025-02-24 | -$78.63M 10-K · filed 2025-02-24 |
| 2023-09-30 | -$23.29M 10-Q · filed 2024-11-07 | -$42.81M derived: sum of 2 quarters · filed 2024-11-07 | -$59.13M 10-Q · filed 2024-11-07 | -$74.07M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$19.52M 10-Q · filed 2024-11-07 | -$35.84M 10-Q · filed 2024-08-08 | -$50.78M derived: sum of 3 quarters · filed 2024-11-07 | -$69.38M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-03-31 | -$16.32M 10-Q · filed 2024-11-07 | -$31.25M derived: sum of 2 quarters · filed 2024-11-07 | -$49.86M derived: sum of 3 quarters · filed 2024-11-07 | -$67.18M derived: sum of 4 quarters · filed 2024-11-07 |
| 2022-12-31 | -$14.94M derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-29 | -$33.54M derived: sum of 2 quarters · filed 2024-03-29 | -$50.86M derived: sum of 3 quarters · filed 2024-03-29 | -$69.10M 10-K/A · filed 2024-03-29 |
| 2022-09-30 | -$18.61M 10-Q · filed 2023-11-08 | -$35.92M derived: sum of 2 quarters · filed 2023-11-08 | -$54.17M 10-Q · filed 2023-11-08 | -$61.31M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-06-30 | -$17.32M 10-Q · filed 2023-11-08 | -$35.56M 10-Q · filed 2023-08-08 | -$42.70M derived: sum of 3 quarters · filed 2023-11-08 | -$50.82M derived: sum of 4 quarters · filed 2023-11-08 |
| 2022-03-31 | -$18.25M 10-Q · filed 2023-11-08 | -$25.39M derived: sum of 2 quarters · filed 2023-11-08 | -$33.50M derived: sum of 3 quarters · filed 2023-11-08 | -$38.89M derived: sum of 4 quarters · filed 2023-11-08 |
| 2021-12-31 | -$7.14M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | -$15.26M derived: sum of 2 quarters · filed 2023-03-23 | -$20.64M derived: sum of 3 quarters · filed 2023-03-23 | -$27.28M 10-K · filed 2023-03-23 |
| 2021-09-30 | -$8.11M 10-Q · filed 2022-11-10 | -$13.50M derived: sum of 2 quarters · filed 2022-11-10 | -$20.14M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | -$5.39M 10-Q · filed 2022-11-10 | -$12.03M 10-Q · filed 2022-08-12 | ||
| 2021-03-31 | -$6.64M 10-Q · filed 2022-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |